AzTrials
AzTrials

Generalized Anxiety DisorderORIGAMINCT05849493

Effects and Mechanisms of Change of Internet Delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder

A study testing Metacognitive Internet delivered Cognitive Behavior Therapy and Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy in people with Generalized Anxiety Disorder, run by Karolinska Institutet at 1 site in Sweden.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to compare two psychological treatments for Generalized Anxiety Disorder. The main questions it aims to answer are: How well do these treatments work compared to earlier studies? Is one of the treatments more effective than the other? Are the treatments working the way that we think… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Generalized Anxiety Disorder
What is being tested?
Metacognitive Internet delivered Cognitive Behavior Therapy and Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteSweden
Study dates
19 May 2023to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years or older.
  • Meet diagnostic criteria for GAD according to DSM-5, as assessed by a psychologist on a video-call.
  • Self-rated score > 10 on GAD-7.
  • Can read and speak Swedish fluently.
  • Have access to a smartphone, tablet, or computer and a Swedish BankID which allows access to the video-calls and treatment platform.
  • Have the time and possibility to participate in the 10 week treatment.
  • Consents to participate.

Who cannot join

  • Patients that are judged to be in greater need of another psychiatric treatment for another psychiatric diagnosis (for example severe depression) and/or is judged to have a high risk of suicide.
  • Current drug or alcohol abuse.
  • Current severe somatic health concern or social vulnerability if this is judged to be too great an obstacle for the patient to carry out the treatment.

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Internet Psychiatry Clinic, Psychiatry Southwest, SLSO, Region Stockholm

    Stockholm, Huddinge, 14135

Other trials in Sweden

About this study

Official title: Effects and Mechanisms of Change of Internet Delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder Based on Intolerance of Uncertainty or Metacognitive Theory

The goal of this clinical trial is to compare two psychological treatments for Generalized Anxiety Disorder. The main questions it aims to answer are:

How well do these treatments work compared to earlier studies? Is one of the treatments more effective than the other? Are the treatments working the way that we think they do? Specifically, do changes in the variables that these treatments aim to target predict changes in anxiety symptoms?

Participants will be randomized to two different internet-based cognitive behavioral therapy (ICBT) programs: Intolerance of uncertainty-based ICBT and metacognition-based ICBT. Both programs consist of 8 treatment modules and run for 10 weeks. A psychologist will respond to the participants assignments and exercises and will respond to messages.

Read the detailed description

A randomized trial will be conducted within the Internet Psychiatry Clinic in Stockholm. An option will be added to the online sign-up form giving potential patients the option to participate in a treatment for GAD as part of this study. Based on information provided in the sign-up-form and an assessment via video-call with a psychologist, patients will be included/excluded.

Included patients will be randomized (1:1) to two different ICBT treatment programs (IU-ICBT and Meta-ICBT). These programs will be implemented into regular care at the Internet Psychiatry Clinic in Stockholm, meaning that each patient will undergo the regular assessment process at the clinic. Both programs are ICBT programs of similar scope, consisting of 8 modules to be completed during 10 weeks. During this time patients read written material which instructs them to do specific exercises, answer specific questions and can message a psychologist at the clinic via the web-platform. Based on similar treatments on the Internet Psychiatry Clinic we expect around 10% drop-out.

The effectiveness of both forms of ICBT (meaning within-group change in symptoms during the ten-week treatment) will be compared to other ICBT studies on GAD. Our criteria for studies to compare are:

  • ICBT as guided self-help, i.e. treatment where the patient is meant to read or otherwise take in pre-written material and is communicating with a psychologist. Not included here are studies on video-call-therapy or chat-bot based treatments.
  • Patients are diagnosed with GAD by a professional, either MD or psychologist.
  • Either GAD-7 or PSWQ exist as an outcome measure.

When comparing the treatment programs to each other the threshold for a clinically relevant difference will be 3 points on the GAD-7 scale. A simulation based power analysis based on estimates from a pilot study of the IU-ICBT protocol has shown that we have well above 95% power when using mixed models, for that equivalence bound and n = 200 per group. Note however that the parameter estimates that goes into that power-analysis is based on only n = 22 patients. For comparison a more simple power-analysis for a post-treatment t-test show n = 200 gives 95% power (rounded up) for an equivalence bound of d = 0.36. Note that equivalence bounds should normally be justified based on clinical grounds rather than statistical; this latter power analysis is thus for illustrative purposes.

Hypothesis 1: IU-ICBT and Meta-ICBT will be effective and equivalent in a benchmarking analysis. (i.e. the estimated outcome at end of treatment will be equivalent, as defined by our equivalence bounds, and the pre-post change will be comparable to other ICBT studies on GAD).

Data-analysis: We plan to use multi-level modeling to utilize the increased power/precision we get from within-participant repeated measures.

Hypothesis 2: Changes in intolerance of uncertainty will statistically mediate the treatment effect in the IU-ICBT group. Changes in negative metacognitive beliefs about worry will statistically mediate the treatment effect in the Meta-ICBT group. The effect of both mediators will be moderated by level of intolerance uncertainty and negative metacognitive beliefs at baseline. We will also compare the putative mediators to each other with the hypothesis that the mediation-effect will be stronger for the specific mediator that a treatment protocol targets. This last analysis is to be regarded as the most severe test of our mediation analysis.

Data-analysis: Participants will fill out weekly questionnaires which will include our putative mediators (MCQ-30 and IU-12 questionnaires) and their current symptom level (GAD-7 questionnaire). The mediation-effect of both treatment protocols will be analyzed using latent growth curve modeling which is considered suitable for the study of moderation and mediation in clinical trials.

Additional hypotheses: In addition to the primary hypotheses, we may also investigate alternative moderators proposed by the literature. Worry behaviors is hypothesised to moderate treatment effect in the IU-ICBT group since that treatment partially has a behavioral treatment focus. Emotional contrast avoidance will also be investigated as a moderator. We will also explore demographic moderators such as gender and education level.

We will also investigate treatment satisfaction using the client satisfaction questionnaire, and treatment credibility using the treatment credibility scale, as well as patient global impressions of improvement.

Being tested
Metacognitive Internet delivered Cognitive Behavior Therapy, Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy
Keywords
internet delivered treatment, digital mental health services, psychiatry, cognitive behavior therapy, intolerance of uncertainty, metacognitive theory, mechanisms of change
Medical subject headings
Generalized Anxiety Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Metacognitive Internet delivered Cognitive Behavior TherapyBehavioural

    Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry

  • Intolerance of uncertainty based Internet delivered Cognitive Behavior TherapyBehavioural

    Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry

Study groups in NCT05849493
Study groupRoleWhat they receive
IU-ICBTExperimental10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist. Based on the Intolerance of uncertainty model of worry.
Receives: Behavioral: Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy
Meta-ICBTExperimental10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist. Based on the Metacognitive model of worry.
Receives: Behavioral: Metacognitive Internet delivered Cognitive Behavior Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Generalized Anxiety Disorder-7 score (GAD-7)

    Measures Generalized Anxiety Symptoms. 7 items. Scores range from 0-21 with higher scores indicating more generalized anxiety

    Measured: From treatment start to 10 weeks after treatment start

  2. Change in Meta-Cognitions Questionnaire-30 score (MCQ-30, negative meta-cognition sub-scale)

    Putative mediator. The MCQ-30 negative subscale measures negative meta-cognitive beliefs about the danger and uncontrollability of worry. 6 items. Scores range from 6-36 with higher scores indicating more negative beliefs about worry.

    Measured: From treatment start to 10 weeks after treatment start

  3. Change in Intolerance of Uncertainty Scale-12 score (IUS-12)

    Putative mediator, measures intolerance of uncertainty. 12 items. Scores range from 12-60 with higher scores indicating more intolerance of uncertainty.

    Measured: From treatment start to 10 weeks after treatment start

Secondary outcomes (8)
  1. Penn-State Worry Questionnaire (PSWQ)

    Measures trait worry. 16 items. Scores range from 16-80 with higher scores indicating more worry.

    Measured: 10 weeks - pre- and post-treatment.

  2. Contrast Avoidance Questionnaire-Worry (CAQ-W)

    measures Contrast Avoidance related to worry. 25 items. Scores range from 30 to 150 with higher scores indicating a higher degree of using worry to avoid emotional contrasts.

    Measured: 10 weeks - pre- and post-treatment.

  3. Montomery-Asberg Depression Rating Scale - Self-rated (MADRS-S)

    Measures depression symptoms. 9 items. Scores range from 0 to 54 with higher scores indicating more depressive symptoms.

    Measured: 10 weeks - pre- and post-treatment.

  4. Meta-Cognitions Qquestionnaire-30 (MCQ-30 - full scale)

    Measures metacognition. 30 items. Scores range from 30-120 with higher scores indicating more potentially dysfunctional metacognitive beliefs about thoughts and worry.

    Measured: 10 weeks - pre- and post-treatment.

  5. Patient Health Questionnaire-9 (PHQ-9)

    Measures depression symptoms. 9 items. Scores range from 0-27 with higher scores indicating more depressive symptoms.

    Measured: 10 weeks - pre- and post-treatment.

  6. World Health Organization Disability Assessment Schedule 2.0

    Measures disability/functional impairment. 12 items. Scores range from 0-48 with higher scores indicating a higher degree of impairment.

    Measured: 10 weeks - pre- and post-treatment.

  7. Client satisfaction questionnaire (adapted to the clinic)

    Measures satisfaction with treatment. 8 items. Scores range from 8-32 with higher scores indicating more satisfaction with the treatment.

    Measured: 10 weeks after treatment start.

  8. Worry Behavior Inventory (WBI)

    Inventory of worry behaviors - 10 items. Scores range from 0-40 with higher scores indicating more frequent worry behaviours.

    Measured: 10 weeks - pre- and post-treatment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 May 2023
  2. Study start19 May 2023
  3. Primary completion1 Sep 2025
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05849493
Sponsor's protocol ID
2022-02380-01-RCT
Acronym
ORIGAMI
Status last verified
Aug 2026
First submitted
4 Apr 2023
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Patient records not available to share.

Questions about this trial

What is this clinical trial studying?

A study testing Metacognitive Internet delivered Cognitive Behavior Therapy and Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy in people with Generalized Anxiety Disorder, run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Generalized Anxiety Disorder-7 score (GAD-7) (time frame: From treatment start to 10 weeks after treatment start). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in